Table 1 Baseline characteristics
From: Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis
Pre-plerixafor era | Plerixafor era | p< | |||
|---|---|---|---|---|---|
(n = 124) | (n = 134) | ||||
Age in years | |||||
Mean (SD) | 54 | (12) | 56 | (11) | |
Median (Q1–Q3) | 57 | (46–63) | 58 | (49–64) | |
Range (min–max) | (22–73) | (20–78) | 0.19 (a) | ||
Height in cm | |||||
Mean (SD) | 171 | (10) | 171 | (10) | |
Median (Q1–Q3) | 172 | (165–178) | 171 | (164–178) | |
Range (min–max) | (150–204) | (143–194) | 0.96 (a) | ||
Weight in kg | |||||
Mean (SD) | 73 | (16) | 73 | (15) | |
Median (Q1–Q3) | 72 | (62–84) | 73 | (62–82) | |
Range (min–max) | (43–140) | (47–118) | 0.90 (a) | ||
Months since diagnosis | |||||
Mean (SD) | 31 | (47) | 27 | (46) | |
Median (Q1–Q3) | 11 | (5–35) | 11 | (5–30) | |
Range (min–max) | (0–216) | (2–270) | 0.93 (b) | ||
Gender | |||||
Female—n (%) | 49 | (40%) | 54 | (40%) | |
Male—n (%) | 75 | (60%) | 80 | (60%) | 0.90 (c) |
Nation | |||||
France—n (%) | 59 | (48%) | 63 | (47%) | |
Germany—n (%) | 39 | (31%) | 51 | (38%) | |
Italy—n (%) | 26 | (21%) | 20 | (15%) | 0.34 (c) |
NHL subtype | |||||
Follicular—n (%) | 27 | (22%) | 32 | (24%) | |
Diffuse—n (%) | 49 | (40%) | 54 | (40%) | |
Mantle—n (%) | 17 | (14%) | 18 | (13%) | |
Other—n (%)a | 31 | (25%) | 30 | (22%) | 0.96 (c) |
Disease stage at diagnosis | |||||
I—n (%) | 6 | (5%) | 6 | (4%) | |
II—n (%) | 10 | (8%) | 19 | (14%) | |
III—n (%) | 17 | (14%) | 18 | (13%) | |
IV—n (%) | 85 | (69%) | 87 | (65%) | |
Unknown—n (%) | 6 | (5%) | 4 | (3%) | 0.58 (c) |
Chemotherapy for mobilizationb | |||||
Rituximab—n (%) | 6 | (5%) | 7 | (5%) | 0.89 (c) |
DHAP/R–DHAP—n (%) | 40 | (32%) | 29 | (22%) | 0.05 (c) |
ESHAP—n (%) | 7 | (6%) | 2 | (1%) | 0.09 (d) |
R-CHOP—n (%) | 16 | (13%) | 15 | (11%) | 0.67 (c) |
Methotrexate—n (%) | 3 | (2%) | 9 | (7%) | 0.10 (c) |
R–ACVBP—n (%) | 3 | (2%) | 3 | (2%) | 1.00 (d) |
Other | 60 | (48%) | 86 | (64%) | 0.01 (c) |
Chemotherapy coursesc | |||||
Mean (SD) | 1.1 | (0.6) | 1.2 | (0.6) | |
Median (Q1–Q3) | 1 | (1–1) | 1 | (1–1) | |
Range (min–max) | (1–5) | (1–5) | 0.11 (b) | ||
Chemotherapy daysc | |||||
Ean (SD) | 4.1 | (5.7) | 4.6 | (5.5) | |
Median (Q1–Q3) | 3 | (1–5) | 4 | (2–5) | |
Range (min–max) | (1–47) | (1–41) | 0.02 (b) | ||
